Molecular Docking Study on Tamoxifen and Toremifene's Effects on the Breast Cancer Receptors

Abstract

Both toremifene (TOR) and tamoxifen (TAM), selective estrogen receptor modulators, are equally effective therapies for breast cancer (BrCa). In high-risk women, anti-estrogenic tamoxifen is frequently used for both (BrCa) treatment and prevention. Another anti-estrogen that is successful in the treatment of (BrCa) is toremifene. Anti-estrogens have emerged as one of the most widely utilized medicine classes among women because (BrCa) is the most frequent malignancy in this population. Consequently, we performed a docking study to assess the effects of tamoxifen and toremifene therapy on the (BrCa) receptor. Tamoxifen and toremifene's interactions with the (BrCa) receptor were examined by a computational study of the ligand's binding. These receptors are named (1jnx), (1n5o), (1oqa), (1t2u), (1t29), (4igk), (4jlu), and (4y2g). All the docking has been done by software named Molecular Operating Environment (MOE) which was used to evaluate the binding docking and docking score between the ligand (TAM or TOR) with the (BrCa) receptors.